FDA Denies Breakthrough Tag For NRx Pharma's COVID-19 Candidate_老虎社区_美港股上老虎

FDA Denies Breakthrough Tag For NRx Pharma's COVID-19 Candidate

Benzinga2021-11-24

Relief Therapeutics Holding SA's collaborating partner NRx Pharmaceuticals Inc has announced that the FDA has denied Breakthrough Therapy Designation for aviptadil. NRx noted that though the ...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

Dad123
·2021-11-24
Like and comment please
回复
3
举报
收起
- SKLow:
  pls like,tq
  2021-11-24
  回复
  举报
Justin8991
·2021-11-24
Ok
回复
3
举报
Trade2retire
·2021-11-24
[Smile]
回复
6
举报
Boonseong
·2021-11-24
[财迷]
回复
6
举报
收起
- Boonseong:
  [财迷]
  2021-11-24
  回复
  举报
nxw
·2021-11-24
Like pls
回复
6
举报
收起
- Dad123:
  Done
  2021-11-24
  回复
  举报
- Justin8991:
  Ok
  2021-11-24
  回复
  举报
- Dollarvan:
  Like pls
  2021-11-24
  回复
  举报
Demonsoh
·2021-11-24
Like please
回复
6
举报
收起
- CuriousPhD:
  Done
  2021-11-24
  回复
  举报
MercaptO
·2021-11-24
☹️
回复
3
举报
收起
- Demonsoh:
  Ok
  2021-11-24
  回复
  举报
- MercaptO:
  👍🏻
  2021-11-24
  回复
  举报
Boonseong
·2021-11-24
[财迷]
回复
5
举报
sockbuster
·2021-11-24
Pls like
回复
4
举报
收起
- lzh77:
  pls like
  2021-11-24
  回复
  举报
ConanToh
·2021-11-24
tiger
回复
4
举报
收起
- nxw:
  Ok
  2021-11-24
  回复
  举报
- sockbuster:
  ok
  2021-11-24
  回复
  举报
- ConanToh:
  good
  2021-11-24
  回复
  举报
CW37
·2021-11-24
tiger
回复
4
举报
收起
- CW37:
  broker
  2021-11-24
  回复
  举报

热议股票

7x24

全部

关于我们·老虎社区守则·老虎社区账号管理规范·老虎社区服务协议·老虎社区隐私政策

公司名称：北京至简风宜信息技术有限公司

违法和不良信息投诉：010-5681-3562（工作时间9:30-18:30）

邮箱：service@laohu8.com

营业执照：91110105MA01A4U55R

ICP备：京ICP备18016422号

网安备：京公网安备11010502036490

关注我们

{"i18n":{"language":"zh_CN"},"data":{"share":"https://www.laohu8.com/m/news/1167653292?lang=zh_CN&edition=full","thumbnail":"","is_english":true,"pubTime":"2021-11-24 22:07","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1167653292","market":"us","top_or_hot":-1,"title":"FDA Denies Breakthrough Tag For NRx Pharma's COVID-19 Candidate","media":"Benzinga","content":"<div>\n<p>Relief Therapeutics Holding SA's collaborating partner NRx Pharmaceuticals Inc has announced that the FDA has denied Breakthrough Therapy Designation for aviptadil.\n\nNRx noted that though the ...</p>\n\n<a href=\"https://www.benzinga.com/general/biotech/21/11/24269339/fda-denies-breakthrough-tag-for-nrx-pharmas-covid-19-candidate\">网页链接</a>\n\n</div>\n","source":"lsy1606299360108","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>FDA Denies Breakthrough Tag For NRx Pharma's COVID-19 Candidate</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nFDA Denies Breakthrough Tag For NRx Pharma's COVID-19 Candidate\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-11-24 22:07 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.benzinga.com/general/biotech/21/11/24269339/fda-denies-breakthrough-tag-for-nrx-pharmas-covid-19-candidate><strong>Benzinga</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Relief Therapeutics Holding SA's collaborating partner NRx Pharmaceuticals Inc has announced that the FDA has denied Breakthrough Therapy Designation for aviptadil.\n\nNRx noted that though the ...</p>\n\n<a href=\"https://www.benzinga.com/general/biotech/21/11/24269339/fda-denies-breakthrough-tag-for-nrx-pharmas-covid-19-candidate\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"NRXP","symbol_name":"NRX Pharmaceuticals Inc.","start_time":0,"source_url":"https://www.benzinga.com/general/biotech/21/11/24269339/fda-denies-breakthrough-tag-for-nrx-pharmas-covid-19-candidate","article_id":"1167653292","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1167653292","pubTimestamp":1637762873,"columns":[],"sourceInfo":{"source_id":"lsy1606299360108","name":"Benzinga"},"weMediaInfo":null,"summary":"Relief Therapeutics Holding SA's collaborating partner NRx Pharmaceuticals Inc has announced that th","collect":0,"end_time":0,"defaultTopTitle":"benzinga.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"NRXP":"NRX Pharmaceuticals Inc.","RLFTF":"RELIEF THERAPEUTICS HLDG AG"},"translate_title":"美国食品和药物管理局否认NRx制药公司新冠肺炎候选人的突破性标签","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"NRXP":0.9,"RLFTF":0.9},"content_text":"Relief Therapeutics Holding SA's collaborating partner NRx Pharmaceuticals Inc has announced that the FDA has denied Breakthrough Therapy Designation for aviptadil.\n\nNRx noted that though the designation is not required for drug approval or emergency use authorization, but can afford faster review times, the ability to submit a rolling application, and dedicated FDA review personnel.\nAdditionally, according to the CEO Update, the FDA has already granted priority and rolling review as part of the Fast Track Designation awarded in July 2020.\nTherefore, the denial does not impede NRx's ability to seek drug approval.\nRelief's lead drug candidate, RLF-100 (aviptadil), is a synthetic form of Vasoactive Intestinal Peptide (VIP).\nIt is in late-stage clinical testing in the U.S. for respiratory deficiency due to COVID-19..\nPrice Action: NRXP shares closed 5.56% lower at $4.25 during after-hours trading on Tuesday.","kind":"news","is_publish_news":true,"is_publish_highlight":true,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[{"id":874608759,"gmtCreate":1637764396437,"gmtModify":1637764396594,"author":{"id":"3581623201234305","authorId":"3581623201234305","name":"Dad123","avatar":"https://static.tigerbbs.com/ac4d85018dddfaed97e09d27a019c74f","vip":1,"crmLevel":1,"crmLevelSwitch":0,"idStr":"3581623201234305","authorIdStr":"3581623201234305"},"htmlText":"Like and comment please&nbsp;","listText":"Like and comment please&nbsp;","text":"Like and comment please","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/874608759","repostId":1167653292,"repostType":4,"repost":{"id":"1167653292","kind":"news","pubTimestamp":1637762873,"share":"https://www.laohu8.com/m/news/1167653292?lang=&edition=full","pubTime":"2021-11-24 22:07","market":"us","language":"en","title":"FDA Denies Breakthrough Tag For NRx Pharma's COVID-19 Candidate","url":"https://stock-news.laohu8.com/highlight/detail?id=1167653292","media":"Benzinga","summary":"Relief Therapeutics Holding SA's collaborating partner NRx Pharmaceuticals Inc has announced that th","content":"<p><b>Relief Therapeutics Holding SA's</b>&nbsp;collaborating partner&nbsp;<b>NRx Pharmaceuticals Inc</b>&nbsp;has announced that the&nbsp;FDA has denied Breakthrough Therapy Designation&nbsp;for aviptadil.</p>\n<ul>\n <li>NRx noted that though the designation is not required for drug approval or emergency use authorization, but can afford faster review times, the ability to submit a rolling application, and dedicated FDA review personnel.</li>\n <li>Additionally, according to the CEO Update, the FDA has already granted priority and rolling review as part of the Fast Track Designation awarded in July 2020.</li>\n <li>Therefore, the denial does not impede NRx's ability to seek drug approval.</li>\n <li>Relief's lead drug candidate, RLF-100 (aviptadil), is a synthetic form of Vasoactive Intestinal Peptide (VIP).</li>\n <li>It is in late-stage clinical testing in the U.S. for respiratory deficiency due to COVID-19.<i>.</i></li>\n <li><b>Price Action:</b>&nbsp;NRXP shares closed 5.56% lower at $4.25 during after-hours trading on Tuesday.</li>\n</ul>","source":"lsy1606299360108","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>FDA Denies Breakthrough Tag For NRx Pharma's COVID-19 Candidate</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nFDA Denies Breakthrough Tag For NRx Pharma's COVID-19 Candidate\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-11-24 22:07 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.benzinga.com/general/biotech/21/11/24269339/fda-denies-breakthrough-tag-for-nrx-pharmas-covid-19-candidate><strong>Benzinga</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Relief Therapeutics Holding SA's collaborating partner NRx Pharmaceuticals Inc has announced that the FDA has denied Breakthrough Therapy Designation for aviptadil.\n\nNRx noted that though the ...</p>\n\n<a href=\"https://www.benzinga.com/general/biotech/21/11/24269339/fda-denies-breakthrough-tag-for-nrx-pharmas-covid-19-candidate\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"RLFTF":"RELIEF THERAPEUTICS HLDG AG","NRXP":"NRX Pharmaceuticals Inc."},"source_url":"https://www.benzinga.com/general/biotech/21/11/24269339/fda-denies-breakthrough-tag-for-nrx-pharmas-covid-19-candidate","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1167653292","content_text":"Relief Therapeutics Holding SA's collaborating partner NRx Pharmaceuticals Inc has announced that the FDA has denied Breakthrough Therapy Designation for aviptadil.\n\nNRx noted that though the designation is not required for drug approval or emergency use authorization, but can afford faster review times, the ability to submit a rolling application, and dedicated FDA review personnel.\nAdditionally, according to the CEO Update, the FDA has already granted priority and rolling review as part of the Fast Track Designation awarded in July 2020.\nTherefore, the denial does not impede NRx's ability to seek drug approval.\nRelief's lead drug candidate, RLF-100 (aviptadil), is a synthetic form of Vasoactive Intestinal Peptide (VIP).\nIt is in late-stage clinical testing in the U.S. for respiratory deficiency due to COVID-19..\nPrice Action: NRXP shares closed 5.56% lower at $4.25 during after-hours trading on Tuesday.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":6709114,"gmtCreate":1637765354197,"gmtModify":1637765354229,"authorId":3582927789816025,"author":{"id":3582927789816025,"idStr":"3582927789816025","authorId":3582927789816025,"name":"SKLow","avatar":"https://static.tigerbbs.com/b3aeaabd2ee1ec9afcdda5a4aab1994c","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":874608759,"type":1,"supId":0,"prevId":0,"content":"pls like,<u>tq</u>","text":"pls like,<u>tq</u>","html":"pls like,<u>tq</u>"}],"langContent":"CN"},{"id":874600536,"gmtCreate":1637764142722,"gmtModify":1637764142826,"author":{"id":"3575292984950927","authorId":"3575292984950927","name":"Justin8991","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":4,"crmLevelSwitch":0,"idStr":"3575292984950927","authorIdStr":"3575292984950927"},"htmlText":"Ok","listText":"Ok","text":"Ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/874600536","repostId":1167653292,"repostType":4,"repost":{"id":"1167653292","kind":"news","pubTimestamp":1637762873,"share":"https://www.laohu8.com/m/news/1167653292?lang=&edition=full","pubTime":"2021-11-24 22:07","market":"us","language":"en","title":"FDA Denies Breakthrough Tag For NRx Pharma's COVID-19 Candidate","url":"https://stock-news.laohu8.com/highlight/detail?id=1167653292","media":"Benzinga","summary":"Relief Therapeutics Holding SA's collaborating partner NRx Pharmaceuticals Inc has announced that th","content":"<p><b>Relief Therapeutics Holding SA's</b>&nbsp;collaborating partner&nbsp;<b>NRx Pharmaceuticals Inc</b>&nbsp;has announced that the&nbsp;FDA has denied Breakthrough Therapy Designation&nbsp;for aviptadil.</p>\n<ul>\n <li>NRx noted that though the designation is not required for drug approval or emergency use authorization, but can afford faster review times, the ability to submit a rolling application, and dedicated FDA review personnel.</li>\n <li>Additionally, according to the CEO Update, the FDA has already granted priority and rolling review as part of the Fast Track Designation awarded in July 2020.</li>\n <li>Therefore, the denial does not impede NRx's ability to seek drug approval.</li>\n <li>Relief's lead drug candidate, RLF-100 (aviptadil), is a synthetic form of Vasoactive Intestinal Peptide (VIP).</li>\n <li>It is in late-stage clinical testing in the U.S. for respiratory deficiency due to COVID-19.<i>.</i></li>\n <li><b>Price Action:</b>&nbsp;NRXP shares closed 5.56% lower at $4.25 during after-hours trading on Tuesday.</li>\n</ul>","source":"lsy1606299360108","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>FDA Denies Breakthrough Tag For NRx Pharma's COVID-19 Candidate</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nFDA Denies Breakthrough Tag For NRx Pharma's COVID-19 Candidate\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-11-24 22:07 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.benzinga.com/general/biotech/21/11/24269339/fda-denies-breakthrough-tag-for-nrx-pharmas-covid-19-candidate><strong>Benzinga</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Relief Therapeutics Holding SA's collaborating partner NRx Pharmaceuticals Inc has announced that the FDA has denied Breakthrough Therapy Designation for aviptadil.\n\nNRx noted that though the ...</p>\n\n<a href=\"https://www.benzinga.com/general/biotech/21/11/24269339/fda-denies-breakthrough-tag-for-nrx-pharmas-covid-19-candidate\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"RLFTF":"RELIEF THERAPEUTICS HLDG AG","NRXP":"NRX Pharmaceuticals Inc."},"source_url":"https://www.benzinga.com/general/biotech/21/11/24269339/fda-denies-breakthrough-tag-for-nrx-pharmas-covid-19-candidate","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1167653292","content_text":"Relief Therapeutics Holding SA's collaborating partner NRx Pharmaceuticals Inc has announced that the FDA has denied Breakthrough Therapy Designation for aviptadil.\n\nNRx noted that though the designation is not required for drug approval or emergency use authorization, but can afford faster review times, the ability to submit a rolling application, and dedicated FDA review personnel.\nAdditionally, according to the CEO Update, the FDA has already granted priority and rolling review as part of the Fast Track Designation awarded in July 2020.\nTherefore, the denial does not impede NRx's ability to seek drug approval.\nRelief's lead drug candidate, RLF-100 (aviptadil), is a synthetic form of Vasoactive Intestinal Peptide (VIP).\nIt is in late-stage clinical testing in the U.S. for respiratory deficiency due to COVID-19..\nPrice Action: NRXP shares closed 5.56% lower at $4.25 during after-hours trading on Tuesday.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"CN"},{"id":874871433,"gmtCreate":1637763290725,"gmtModify":1637763290856,"author":{"id":"3576159555258706","authorId":"3576159555258706","name":"Trade2retire","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":8,"crmLevelSwitch":0,"idStr":"3576159555258706","authorIdStr":"3576159555258706"},"htmlText":"[Smile]&nbsp;","listText":"[Smile]&nbsp;","text":"[Smile]","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/874871433","repostId":1167653292,"repostType":4,"repost":{"id":"1167653292","kind":"news","pubTimestamp":1637762873,"share":"https://www.laohu8.com/m/news/1167653292?lang=&edition=full","pubTime":"2021-11-24 22:07","market":"us","language":"en","title":"FDA Denies Breakthrough Tag For NRx Pharma's COVID-19 Candidate","url":"https://stock-news.laohu8.com/highlight/detail?id=1167653292","media":"Benzinga","summary":"Relief Therapeutics Holding SA's collaborating partner NRx Pharmaceuticals Inc has announced that th","content":"<p><b>Relief Therapeutics Holding SA's</b>&nbsp;collaborating partner&nbsp;<b>NRx Pharmaceuticals Inc</b>&nbsp;has announced that the&nbsp;FDA has denied Breakthrough Therapy Designation&nbsp;for aviptadil.</p>\n<ul>\n <li>NRx noted that though the designation is not required for drug approval or emergency use authorization, but can afford faster review times, the ability to submit a rolling application, and dedicated FDA review personnel.</li>\n <li>Additionally, according to the CEO Update, the FDA has already granted priority and rolling review as part of the Fast Track Designation awarded in July 2020.</li>\n <li>Therefore, the denial does not impede NRx's ability to seek drug approval.</li>\n <li>Relief's lead drug candidate, RLF-100 (aviptadil), is a synthetic form of Vasoactive Intestinal Peptide (VIP).</li>\n <li>It is in late-stage clinical testing in the U.S. for respiratory deficiency due to COVID-19.<i>.</i></li>\n <li><b>Price Action:</b>&nbsp;NRXP shares closed 5.56% lower at $4.25 during after-hours trading on Tuesday.</li>\n</ul>","source":"lsy1606299360108","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>FDA Denies Breakthrough Tag For NRx Pharma's COVID-19 Candidate</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nFDA Denies Breakthrough Tag For NRx Pharma's COVID-19 Candidate\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-11-24 22:07 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.benzinga.com/general/biotech/21/11/24269339/fda-denies-breakthrough-tag-for-nrx-pharmas-covid-19-candidate><strong>Benzinga</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Relief Therapeutics Holding SA's collaborating partner NRx Pharmaceuticals Inc has announced that the FDA has denied Breakthrough Therapy Designation for aviptadil.\n\nNRx noted that though the ...</p>\n\n<a href=\"https://www.benzinga.com/general/biotech/21/11/24269339/fda-denies-breakthrough-tag-for-nrx-pharmas-covid-19-candidate\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"RLFTF":"RELIEF THERAPEUTICS HLDG AG","NRXP":"NRX Pharmaceuticals Inc."},"source_url":"https://www.benzinga.com/general/biotech/21/11/24269339/fda-denies-breakthrough-tag-for-nrx-pharmas-covid-19-candidate","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1167653292","content_text":"Relief Therapeutics Holding SA's collaborating partner NRx Pharmaceuticals Inc has announced that the FDA has denied Breakthrough Therapy Designation for aviptadil.\n\nNRx noted that though the designation is not required for drug approval or emergency use authorization, but can afford faster review times, the ability to submit a rolling application, and dedicated FDA review personnel.\nAdditionally, according to the CEO Update, the FDA has already granted priority and rolling review as part of the Fast Track Designation awarded in July 2020.\nTherefore, the denial does not impede NRx's ability to seek drug approval.\nRelief's lead drug candidate, RLF-100 (aviptadil), is a synthetic form of Vasoactive Intestinal Peptide (VIP).\nIt is in late-stage clinical testing in the U.S. for respiratory deficiency due to COVID-19..\nPrice Action: NRXP shares closed 5.56% lower at $4.25 during after-hours trading on Tuesday.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"CN"},{"id":874871540,"gmtCreate":1637763288623,"gmtModify":1637763288762,"author":{"id":"3585729801280242","authorId":"3585729801280242","name":"Boonseong","avatar":"https://static.tigerbbs.com/246facebf009ccbd87b47e3e304c37ef","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"3585729801280242","authorIdStr":"3585729801280242"},"htmlText":"[财迷]&nbsp;","listText":"[财迷]&nbsp;","text":"[财迷]","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/874871540","repostId":1167653292,"repostType":4,"repost":{"id":"1167653292","kind":"news","pubTimestamp":1637762873,"share":"https://www.laohu8.com/m/news/1167653292?lang=&edition=full","pubTime":"2021-11-24 22:07","market":"us","language":"en","title":"FDA Denies Breakthrough Tag For NRx Pharma's COVID-19 Candidate","url":"https://stock-news.laohu8.com/highlight/detail?id=1167653292","media":"Benzinga","summary":"Relief Therapeutics Holding SA's collaborating partner NRx Pharmaceuticals Inc has announced that th","content":"<p><b>Relief Therapeutics Holding SA's</b>&nbsp;collaborating partner&nbsp;<b>NRx Pharmaceuticals Inc</b>&nbsp;has announced that the&nbsp;FDA has denied Breakthrough Therapy Designation&nbsp;for aviptadil.</p>\n<ul>\n <li>NRx noted that though the designation is not required for drug approval or emergency use authorization, but can afford faster review times, the ability to submit a rolling application, and dedicated FDA review personnel.</li>\n <li>Additionally, according to the CEO Update, the FDA has already granted priority and rolling review as part of the Fast Track Designation awarded in July 2020.</li>\n <li>Therefore, the denial does not impede NRx's ability to seek drug approval.</li>\n <li>Relief's lead drug candidate, RLF-100 (aviptadil), is a synthetic form of Vasoactive Intestinal Peptide (VIP).</li>\n <li>It is in late-stage clinical testing in the U.S. for respiratory deficiency due to COVID-19.<i>.</i></li>\n <li><b>Price Action:</b>&nbsp;NRXP shares closed 5.56% lower at $4.25 during after-hours trading on Tuesday.</li>\n</ul>","source":"lsy1606299360108","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>FDA Denies Breakthrough Tag For NRx Pharma's COVID-19 Candidate</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nFDA Denies Breakthrough Tag For NRx Pharma's COVID-19 Candidate\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-11-24 22:07 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.benzinga.com/general/biotech/21/11/24269339/fda-denies-breakthrough-tag-for-nrx-pharmas-covid-19-candidate><strong>Benzinga</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Relief Therapeutics Holding SA's collaborating partner NRx Pharmaceuticals Inc has announced that the FDA has denied Breakthrough Therapy Designation for aviptadil.\n\nNRx noted that though the ...</p>\n\n<a href=\"https://www.benzinga.com/general/biotech/21/11/24269339/fda-denies-breakthrough-tag-for-nrx-pharmas-covid-19-candidate\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"RLFTF":"RELIEF THERAPEUTICS HLDG AG","NRXP":"NRX Pharmaceuticals Inc."},"source_url":"https://www.benzinga.com/general/biotech/21/11/24269339/fda-denies-breakthrough-tag-for-nrx-pharmas-covid-19-candidate","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1167653292","content_text":"Relief Therapeutics Holding SA's collaborating partner NRx Pharmaceuticals Inc has announced that the FDA has denied Breakthrough Therapy Designation for aviptadil.\n\nNRx noted that though the designation is not required for drug approval or emergency use authorization, but can afford faster review times, the ability to submit a rolling application, and dedicated FDA review personnel.\nAdditionally, according to the CEO Update, the FDA has already granted priority and rolling review as part of the Fast Track Designation awarded in July 2020.\nTherefore, the denial does not impede NRx's ability to seek drug approval.\nRelief's lead drug candidate, RLF-100 (aviptadil), is a synthetic form of Vasoactive Intestinal Peptide (VIP).\nIt is in late-stage clinical testing in the U.S. for respiratory deficiency due to COVID-19..\nPrice Action: NRXP shares closed 5.56% lower at $4.25 during after-hours trading on Tuesday.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":6708509,"gmtCreate":1637763302491,"gmtModify":1637763302580,"authorId":3585729801280242,"author":{"id":3585729801280242,"idStr":"3585729801280242","authorId":3585729801280242,"name":"Boonseong","avatar":"https://static.tigerbbs.com/246facebf009ccbd87b47e3e304c37ef","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":874871540,"type":1,"supId":0,"prevId":0,"content":"[财迷]","text":"[财迷]","html":"[财迷]"}],"langContent":"CN"},{"id":874871358,"gmtCreate":1637763260314,"gmtModify":1637763260539,"author":{"id":"3555755639757611","authorId":"3555755639757611","name":"nxw","avatar":"https://static.tigerbbs.com/0a3041e78835567c8db5934504534a17","vip":1,"crmLevel":5,"crmLevelSwitch":0,"idStr":"3555755639757611","authorIdStr":"3555755639757611"},"htmlText":"Like pls","listText":"Like pls","text":"Like pls","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":3,"repostSize":0,"link":"https://laohu8.com/post/874871358","repostId":1167653292,"repostType":4,"repost":{"id":"1167653292","kind":"news","pubTimestamp":1637762873,"share":"https://www.laohu8.com/m/news/1167653292?lang=&edition=full","pubTime":"2021-11-24 22:07","market":"us","language":"en","title":"FDA Denies Breakthrough Tag For NRx Pharma's COVID-19 Candidate","url":"https://stock-news.laohu8.com/highlight/detail?id=1167653292","media":"Benzinga","summary":"Relief Therapeutics Holding SA's collaborating partner NRx Pharmaceuticals Inc has announced that th","content":"<p><b>Relief Therapeutics Holding SA's</b>&nbsp;collaborating partner&nbsp;<b>NRx Pharmaceuticals Inc</b>&nbsp;has announced that the&nbsp;FDA has denied Breakthrough Therapy Designation&nbsp;for aviptadil.</p>\n<ul>\n <li>NRx noted that though the designation is not required for drug approval or emergency use authorization, but can afford faster review times, the ability to submit a rolling application, and dedicated FDA review personnel.</li>\n <li>Additionally, according to the CEO Update, the FDA has already granted priority and rolling review as part of the Fast Track Designation awarded in July 2020.</li>\n <li>Therefore, the denial does not impede NRx's ability to seek drug approval.</li>\n <li>Relief's lead drug candidate, RLF-100 (aviptadil), is a synthetic form of Vasoactive Intestinal Peptide (VIP).</li>\n <li>It is in late-stage clinical testing in the U.S. for respiratory deficiency due to COVID-19.<i>.</i></li>\n <li><b>Price Action:</b>&nbsp;NRXP shares closed 5.56% lower at $4.25 during after-hours trading on Tuesday.</li>\n</ul>","source":"lsy1606299360108","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>FDA Denies Breakthrough Tag For NRx Pharma's COVID-19 Candidate</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nFDA Denies Breakthrough Tag For NRx Pharma's COVID-19 Candidate\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-11-24 22:07 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.benzinga.com/general/biotech/21/11/24269339/fda-denies-breakthrough-tag-for-nrx-pharmas-covid-19-candidate><strong>Benzinga</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Relief Therapeutics Holding SA's collaborating partner NRx Pharmaceuticals Inc has announced that the FDA has denied Breakthrough Therapy Designation for aviptadil.\n\nNRx noted that though the ...</p>\n\n<a href=\"https://www.benzinga.com/general/biotech/21/11/24269339/fda-denies-breakthrough-tag-for-nrx-pharmas-covid-19-candidate\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"RLFTF":"RELIEF THERAPEUTICS HLDG AG","NRXP":"NRX Pharmaceuticals Inc."},"source_url":"https://www.benzinga.com/general/biotech/21/11/24269339/fda-denies-breakthrough-tag-for-nrx-pharmas-covid-19-candidate","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1167653292","content_text":"Relief Therapeutics Holding SA's collaborating partner NRx Pharmaceuticals Inc has announced that the FDA has denied Breakthrough Therapy Designation for aviptadil.\n\nNRx noted that though the designation is not required for drug approval or emergency use authorization, but can afford faster review times, the ability to submit a rolling application, and dedicated FDA review personnel.\nAdditionally, according to the CEO Update, the FDA has already granted priority and rolling review as part of the Fast Track Designation awarded in July 2020.\nTherefore, the denial does not impede NRx's ability to seek drug approval.\nRelief's lead drug candidate, RLF-100 (aviptadil), is a synthetic form of Vasoactive Intestinal Peptide (VIP).\nIt is in late-stage clinical testing in the U.S. for respiratory deficiency due to COVID-19..\nPrice Action: NRXP shares closed 5.56% lower at $4.25 during after-hours trading on Tuesday.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":6708790,"gmtCreate":1637764407348,"gmtModify":1637764407382,"authorId":3581623201234305,"author":{"id":3581623201234305,"idStr":"3581623201234305","authorId":3581623201234305,"name":"Dad123","avatar":"https://static.tigerbbs.com/ac4d85018dddfaed97e09d27a019c74f","vip":1,"crmLevel":1,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":874871358,"type":1,"supId":0,"prevId":0,"content":"Done","text":"Done","html":"Done"},{"id":6708729,"gmtCreate":1637764190682,"gmtModify":1637764190769,"authorId":3575292984950927,"author":{"id":3575292984950927,"idStr":"3575292984950927","authorId":3575292984950927,"name":"Justin8991","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":4,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":874871358,"type":1,"supId":0,"prevId":0,"content":"Ok","text":"Ok","html":"Ok"},{"id":6708591,"gmtCreate":1637763563033,"gmtModify":1637763563062,"authorId":3555014251535651,"author":{"id":3555014251535651,"idStr":"3555014251535651","authorId":3555014251535651,"name":"Dollarvan","avatar":"https://static.tigerbbs.com/0316ab12b442ee2cd79936de06de5089","vip":1,"crmLevel":5,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":874871358,"type":1,"supId":0,"prevId":0,"content":"Like pls","text":"Like pls","html":"Like pls"}],"langContent":"CN"},{"id":874873453,"gmtCreate":1637763222850,"gmtModify":1637763222930,"author":{"id":"3586616403399133","authorId":"3586616403399133","name":"Demonsoh","avatar":"https://static.tigerbbs.com/bfc41482583c4b0bdc313eb042de776e","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"3586616403399133","authorIdStr":"3586616403399133"},"htmlText":"Like please&nbsp;","listText":"Like please&nbsp;","text":"Like please","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/874873453","repostId":1167653292,"repostType":4,"repost":{"id":"1167653292","kind":"news","pubTimestamp":1637762873,"share":"https://www.laohu8.com/m/news/1167653292?lang=&edition=full","pubTime":"2021-11-24 22:07","market":"us","language":"en","title":"FDA Denies Breakthrough Tag For NRx Pharma's COVID-19 Candidate","url":"https://stock-news.laohu8.com/highlight/detail?id=1167653292","media":"Benzinga","summary":"Relief Therapeutics Holding SA's collaborating partner NRx Pharmaceuticals Inc has announced that th","content":"<p><b>Relief Therapeutics Holding SA's</b>&nbsp;collaborating partner&nbsp;<b>NRx Pharmaceuticals Inc</b>&nbsp;has announced that the&nbsp;FDA has denied Breakthrough Therapy Designation&nbsp;for aviptadil.</p>\n<ul>\n <li>NRx noted that though the designation is not required for drug approval or emergency use authorization, but can afford faster review times, the ability to submit a rolling application, and dedicated FDA review personnel.</li>\n <li>Additionally, according to the CEO Update, the FDA has already granted priority and rolling review as part of the Fast Track Designation awarded in July 2020.</li>\n <li>Therefore, the denial does not impede NRx's ability to seek drug approval.</li>\n <li>Relief's lead drug candidate, RLF-100 (aviptadil), is a synthetic form of Vasoactive Intestinal Peptide (VIP).</li>\n <li>It is in late-stage clinical testing in the U.S. for respiratory deficiency due to COVID-19.<i>.</i></li>\n <li><b>Price Action:</b>&nbsp;NRXP shares closed 5.56% lower at $4.25 during after-hours trading on Tuesday.</li>\n</ul>","source":"lsy1606299360108","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>FDA Denies Breakthrough Tag For NRx Pharma's COVID-19 Candidate</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nFDA Denies Breakthrough Tag For NRx Pharma's COVID-19 Candidate\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-11-24 22:07 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.benzinga.com/general/biotech/21/11/24269339/fda-denies-breakthrough-tag-for-nrx-pharmas-covid-19-candidate><strong>Benzinga</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Relief Therapeutics Holding SA's collaborating partner NRx Pharmaceuticals Inc has announced that the FDA has denied Breakthrough Therapy Designation for aviptadil.\n\nNRx noted that though the ...</p>\n\n<a href=\"https://www.benzinga.com/general/biotech/21/11/24269339/fda-denies-breakthrough-tag-for-nrx-pharmas-covid-19-candidate\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"RLFTF":"RELIEF THERAPEUTICS HLDG AG","NRXP":"NRX Pharmaceuticals Inc."},"source_url":"https://www.benzinga.com/general/biotech/21/11/24269339/fda-denies-breakthrough-tag-for-nrx-pharmas-covid-19-candidate","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1167653292","content_text":"Relief Therapeutics Holding SA's collaborating partner NRx Pharmaceuticals Inc has announced that the FDA has denied Breakthrough Therapy Designation for aviptadil.\n\nNRx noted that though the designation is not required for drug approval or emergency use authorization, but can afford faster review times, the ability to submit a rolling application, and dedicated FDA review personnel.\nAdditionally, according to the CEO Update, the FDA has already granted priority and rolling review as part of the Fast Track Designation awarded in July 2020.\nTherefore, the denial does not impede NRx's ability to seek drug approval.\nRelief's lead drug candidate, RLF-100 (aviptadil), is a synthetic form of Vasoactive Intestinal Peptide (VIP).\nIt is in late-stage clinical testing in the U.S. for respiratory deficiency due to COVID-19..\nPrice Action: NRXP shares closed 5.56% lower at $4.25 during after-hours trading on Tuesday.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":6708726,"gmtCreate":1637764161801,"gmtModify":1637764161895,"authorId":3581629167637532,"author":{"id":3581629167637532,"idStr":"3581629167637532","authorId":3581629167637532,"name":"CuriousPhD","avatar":"https://static.tigerbbs.com/6f2eb06a7bbc1da3f700038e46d4e807","vip":1,"crmLevel":6,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":874873453,"type":1,"supId":0,"prevId":0,"content":"Done","text":"Done","html":"Done"}],"langContent":"CN"},{"id":874873591,"gmtCreate":1637763222010,"gmtModify":1637763222139,"author":{"id":"3581825680020062","authorId":"3581825680020062","name":"MercaptO","avatar":"https://static.tigerbbs.com/b6b47c556493b5afdfc573962162dc8f","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"3581825680020062","authorIdStr":"3581825680020062"},"htmlText":"☹️","listText":"☹️","text":"☹️","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/874873591","repostId":1167653292,"repostType":4,"repost":{"id":"1167653292","kind":"news","pubTimestamp":1637762873,"share":"https://www.laohu8.com/m/news/1167653292?lang=&edition=full","pubTime":"2021-11-24 22:07","market":"us","language":"en","title":"FDA Denies Breakthrough Tag For NRx Pharma's COVID-19 Candidate","url":"https://stock-news.laohu8.com/highlight/detail?id=1167653292","media":"Benzinga","summary":"Relief Therapeutics Holding SA's collaborating partner NRx Pharmaceuticals Inc has announced that th","content":"<p><b>Relief Therapeutics Holding SA's</b>&nbsp;collaborating partner&nbsp;<b>NRx Pharmaceuticals Inc</b>&nbsp;has announced that the&nbsp;FDA has denied Breakthrough Therapy Designation&nbsp;for aviptadil.</p>\n<ul>\n <li>NRx noted that though the designation is not required for drug approval or emergency use authorization, but can afford faster review times, the ability to submit a rolling application, and dedicated FDA review personnel.</li>\n <li>Additionally, according to the CEO Update, the FDA has already granted priority and rolling review as part of the Fast Track Designation awarded in July 2020.</li>\n <li>Therefore, the denial does not impede NRx's ability to seek drug approval.</li>\n <li>Relief's lead drug candidate, RLF-100 (aviptadil), is a synthetic form of Vasoactive Intestinal Peptide (VIP).</li>\n <li>It is in late-stage clinical testing in the U.S. for respiratory deficiency due to COVID-19.<i>.</i></li>\n <li><b>Price Action:</b>&nbsp;NRXP shares closed 5.56% lower at $4.25 during after-hours trading on Tuesday.</li>\n</ul>","source":"lsy1606299360108","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>FDA Denies Breakthrough Tag For NRx Pharma's COVID-19 Candidate</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nFDA Denies Breakthrough Tag For NRx Pharma's COVID-19 Candidate\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-11-24 22:07 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.benzinga.com/general/biotech/21/11/24269339/fda-denies-breakthrough-tag-for-nrx-pharmas-covid-19-candidate><strong>Benzinga</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Relief Therapeutics Holding SA's collaborating partner NRx Pharmaceuticals Inc has announced that the FDA has denied Breakthrough Therapy Designation for aviptadil.\n\nNRx noted that though the ...</p>\n\n<a href=\"https://www.benzinga.com/general/biotech/21/11/24269339/fda-denies-breakthrough-tag-for-nrx-pharmas-covid-19-candidate\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"RLFTF":"RELIEF THERAPEUTICS HLDG AG","NRXP":"NRX Pharmaceuticals Inc."},"source_url":"https://www.benzinga.com/general/biotech/21/11/24269339/fda-denies-breakthrough-tag-for-nrx-pharmas-covid-19-candidate","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1167653292","content_text":"Relief Therapeutics Holding SA's collaborating partner NRx Pharmaceuticals Inc has announced that the FDA has denied Breakthrough Therapy Designation for aviptadil.\n\nNRx noted that though the designation is not required for drug approval or emergency use authorization, but can afford faster review times, the ability to submit a rolling application, and dedicated FDA review personnel.\nAdditionally, according to the CEO Update, the FDA has already granted priority and rolling review as part of the Fast Track Designation awarded in July 2020.\nTherefore, the denial does not impede NRx's ability to seek drug approval.\nRelief's lead drug candidate, RLF-100 (aviptadil), is a synthetic form of Vasoactive Intestinal Peptide (VIP).\nIt is in late-stage clinical testing in the U.S. for respiratory deficiency due to COVID-19..\nPrice Action: NRXP shares closed 5.56% lower at $4.25 during after-hours trading on Tuesday.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":6708481,"gmtCreate":1637763228925,"gmtModify":1637763229014,"authorId":3586616403399133,"author":{"id":3586616403399133,"idStr":"3586616403399133","authorId":3586616403399133,"name":"Demonsoh","avatar":"https://static.tigerbbs.com/bfc41482583c4b0bdc313eb042de776e","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":874873591,"type":1,"supId":0,"prevId":0,"content":"Ok","text":"Ok","html":"Ok"},{"id":6708480,"gmtCreate":1637763228317,"gmtModify":1637763228342,"authorId":3581825680020062,"author":{"id":3581825680020062,"idStr":"3581825680020062","authorId":3581825680020062,"name":"MercaptO","avatar":"https://static.tigerbbs.com/b6b47c556493b5afdfc573962162dc8f","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":874873591,"type":1,"supId":0,"prevId":0,"content":"👍🏻","text":"👍🏻","html":"👍🏻"}],"langContent":"CN"},{"id":874873612,"gmtCreate":1637763174799,"gmtModify":1637763174894,"author":{"id":"3585729801280242","authorId":"3585729801280242","name":"Boonseong","avatar":"https://static.tigerbbs.com/246facebf009ccbd87b47e3e304c37ef","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"3585729801280242","authorIdStr":"3585729801280242"},"htmlText":"[财迷]&nbsp;","listText":"[财迷]&nbsp;","text":"[财迷]","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/874873612","repostId":1167653292,"repostType":4,"repost":{"id":"1167653292","kind":"news","pubTimestamp":1637762873,"share":"https://www.laohu8.com/m/news/1167653292?lang=&edition=full","pubTime":"2021-11-24 22:07","market":"us","language":"en","title":"FDA Denies Breakthrough Tag For NRx Pharma's COVID-19 Candidate","url":"https://stock-news.laohu8.com/highlight/detail?id=1167653292","media":"Benzinga","summary":"Relief Therapeutics Holding SA's collaborating partner NRx Pharmaceuticals Inc has announced that th","content":"<p><b>Relief Therapeutics Holding SA's</b>&nbsp;collaborating partner&nbsp;<b>NRx Pharmaceuticals Inc</b>&nbsp;has announced that the&nbsp;FDA has denied Breakthrough Therapy Designation&nbsp;for aviptadil.</p>\n<ul>\n <li>NRx noted that though the designation is not required for drug approval or emergency use authorization, but can afford faster review times, the ability to submit a rolling application, and dedicated FDA review personnel.</li>\n <li>Additionally, according to the CEO Update, the FDA has already granted priority and rolling review as part of the Fast Track Designation awarded in July 2020.</li>\n <li>Therefore, the denial does not impede NRx's ability to seek drug approval.</li>\n <li>Relief's lead drug candidate, RLF-100 (aviptadil), is a synthetic form of Vasoactive Intestinal Peptide (VIP).</li>\n <li>It is in late-stage clinical testing in the U.S. for respiratory deficiency due to COVID-19.<i>.</i></li>\n <li><b>Price Action:</b>&nbsp;NRXP shares closed 5.56% lower at $4.25 during after-hours trading on Tuesday.</li>\n</ul>","source":"lsy1606299360108","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>FDA Denies Breakthrough Tag For NRx Pharma's COVID-19 Candidate</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nFDA Denies Breakthrough Tag For NRx Pharma's COVID-19 Candidate\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-11-24 22:07 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.benzinga.com/general/biotech/21/11/24269339/fda-denies-breakthrough-tag-for-nrx-pharmas-covid-19-candidate><strong>Benzinga</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Relief Therapeutics Holding SA's collaborating partner NRx Pharmaceuticals Inc has announced that the FDA has denied Breakthrough Therapy Designation for aviptadil.\n\nNRx noted that though the ...</p>\n\n<a href=\"https://www.benzinga.com/general/biotech/21/11/24269339/fda-denies-breakthrough-tag-for-nrx-pharmas-covid-19-candidate\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"RLFTF":"RELIEF THERAPEUTICS HLDG AG","NRXP":"NRX Pharmaceuticals Inc."},"source_url":"https://www.benzinga.com/general/biotech/21/11/24269339/fda-denies-breakthrough-tag-for-nrx-pharmas-covid-19-candidate","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1167653292","content_text":"Relief Therapeutics Holding SA's collaborating partner NRx Pharmaceuticals Inc has announced that the FDA has denied Breakthrough Therapy Designation for aviptadil.\n\nNRx noted that though the designation is not required for drug approval or emergency use authorization, but can afford faster review times, the ability to submit a rolling application, and dedicated FDA review personnel.\nAdditionally, according to the CEO Update, the FDA has already granted priority and rolling review as part of the Fast Track Designation awarded in July 2020.\nTherefore, the denial does not impede NRx's ability to seek drug approval.\nRelief's lead drug candidate, RLF-100 (aviptadil), is a synthetic form of Vasoactive Intestinal Peptide (VIP).\nIt is in late-stage clinical testing in the U.S. for respiratory deficiency due to COVID-19..\nPrice Action: NRXP shares closed 5.56% lower at $4.25 during after-hours trading on Tuesday.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"CN"},{"id":874873844,"gmtCreate":1637763156381,"gmtModify":1637763159127,"author":{"id":"3580889175020769","authorId":"3580889175020769","name":"sockbuster","avatar":"https://static.tigerbbs.com/902e4c3353374f5915d6b7fecf6ec383","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"3580889175020769","authorIdStr":"3580889175020769"},"htmlText":"Pls like","listText":"Pls like","text":"Pls like","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/874873844","repostId":1167653292,"repostType":4,"repost":{"id":"1167653292","kind":"news","pubTimestamp":1637762873,"share":"https://www.laohu8.com/m/news/1167653292?lang=&edition=full","pubTime":"2021-11-24 22:07","market":"us","language":"en","title":"FDA Denies Breakthrough Tag For NRx Pharma's COVID-19 Candidate","url":"https://stock-news.laohu8.com/highlight/detail?id=1167653292","media":"Benzinga","summary":"Relief Therapeutics Holding SA's collaborating partner NRx Pharmaceuticals Inc has announced that th","content":"<p><b>Relief Therapeutics Holding SA's</b>&nbsp;collaborating partner&nbsp;<b>NRx Pharmaceuticals Inc</b>&nbsp;has announced that the&nbsp;FDA has denied Breakthrough Therapy Designation&nbsp;for aviptadil.</p>\n<ul>\n <li>NRx noted that though the designation is not required for drug approval or emergency use authorization, but can afford faster review times, the ability to submit a rolling application, and dedicated FDA review personnel.</li>\n <li>Additionally, according to the CEO Update, the FDA has already granted priority and rolling review as part of the Fast Track Designation awarded in July 2020.</li>\n <li>Therefore, the denial does not impede NRx's ability to seek drug approval.</li>\n <li>Relief's lead drug candidate, RLF-100 (aviptadil), is a synthetic form of Vasoactive Intestinal Peptide (VIP).</li>\n <li>It is in late-stage clinical testing in the U.S. for respiratory deficiency due to COVID-19.<i>.</i></li>\n <li><b>Price Action:</b>&nbsp;NRXP shares closed 5.56% lower at $4.25 during after-hours trading on Tuesday.</li>\n</ul>","source":"lsy1606299360108","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>FDA Denies Breakthrough Tag For NRx Pharma's COVID-19 Candidate</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nFDA Denies Breakthrough Tag For NRx Pharma's COVID-19 Candidate\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-11-24 22:07 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.benzinga.com/general/biotech/21/11/24269339/fda-denies-breakthrough-tag-for-nrx-pharmas-covid-19-candidate><strong>Benzinga</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Relief Therapeutics Holding SA's collaborating partner NRx Pharmaceuticals Inc has announced that the FDA has denied Breakthrough Therapy Designation for aviptadil.\n\nNRx noted that though the ...</p>\n\n<a href=\"https://www.benzinga.com/general/biotech/21/11/24269339/fda-denies-breakthrough-tag-for-nrx-pharmas-covid-19-candidate\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"RLFTF":"RELIEF THERAPEUTICS HLDG AG","NRXP":"NRX Pharmaceuticals Inc."},"source_url":"https://www.benzinga.com/general/biotech/21/11/24269339/fda-denies-breakthrough-tag-for-nrx-pharmas-covid-19-candidate","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1167653292","content_text":"Relief Therapeutics Holding SA's collaborating partner NRx Pharmaceuticals Inc has announced that the FDA has denied Breakthrough Therapy Designation for aviptadil.\n\nNRx noted that though the designation is not required for drug approval or emergency use authorization, but can afford faster review times, the ability to submit a rolling application, and dedicated FDA review personnel.\nAdditionally, according to the CEO Update, the FDA has already granted priority and rolling review as part of the Fast Track Designation awarded in July 2020.\nTherefore, the denial does not impede NRx's ability to seek drug approval.\nRelief's lead drug candidate, RLF-100 (aviptadil), is a synthetic form of Vasoactive Intestinal Peptide (VIP).\nIt is in late-stage clinical testing in the U.S. for respiratory deficiency due to COVID-19..\nPrice Action: NRXP shares closed 5.56% lower at $4.25 during after-hours trading on Tuesday.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":6708468,"gmtCreate":1637763186783,"gmtModify":1637763186878,"authorId":3581654499912172,"author":{"id":3581654499912172,"idStr":"3581654499912172","authorId":3581654499912172,"name":"lzh77","avatar":"https://static.tigerbbs.com/37282f661827d98da9d277ecf852cb00","vip":1,"crmLevel":5,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":874873844,"type":1,"supId":0,"prevId":0,"content":"pls like","text":"pls like","html":"pls like"}],"langContent":"CN"},{"id":874879942,"gmtCreate":1637763058364,"gmtModify":1637763226128,"author":{"id":"3578621924333526","authorId":"3578621924333526","name":"ConanToh","avatar":"https://static.tigerbbs.com/17bf1e09858b72f85e5e8efda2fbed84","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"3578621924333526","authorIdStr":"3578621924333526"},"htmlText":"tiger","listText":"tiger","text":"tiger","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":3,"repostSize":0,"link":"https://laohu8.com/post/874879942","repostId":1167653292,"repostType":4,"repost":{"id":"1167653292","kind":"news","pubTimestamp":1637762873,"share":"https://www.laohu8.com/m/news/1167653292?lang=&edition=full","pubTime":"2021-11-24 22:07","market":"us","language":"en","title":"FDA Denies Breakthrough Tag For NRx Pharma's COVID-19 Candidate","url":"https://stock-news.laohu8.com/highlight/detail?id=1167653292","media":"Benzinga","summary":"Relief Therapeutics Holding SA's collaborating partner NRx Pharmaceuticals Inc has announced that th","content":"<p><b>Relief Therapeutics Holding SA's</b>&nbsp;collaborating partner&nbsp;<b>NRx Pharmaceuticals Inc</b>&nbsp;has announced that the&nbsp;FDA has denied Breakthrough Therapy Designation&nbsp;for aviptadil.</p>\n<ul>\n <li>NRx noted that though the designation is not required for drug approval or emergency use authorization, but can afford faster review times, the ability to submit a rolling application, and dedicated FDA review personnel.</li>\n <li>Additionally, according to the CEO Update, the FDA has already granted priority and rolling review as part of the Fast Track Designation awarded in July 2020.</li>\n <li>Therefore, the denial does not impede NRx's ability to seek drug approval.</li>\n <li>Relief's lead drug candidate, RLF-100 (aviptadil), is a synthetic form of Vasoactive Intestinal Peptide (VIP).</li>\n <li>It is in late-stage clinical testing in the U.S. for respiratory deficiency due to COVID-19.<i>.</i></li>\n <li><b>Price Action:</b>&nbsp;NRXP shares closed 5.56% lower at $4.25 during after-hours trading on Tuesday.</li>\n</ul>","source":"lsy1606299360108","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>FDA Denies Breakthrough Tag For NRx Pharma's COVID-19 Candidate</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nFDA Denies Breakthrough Tag For NRx Pharma's COVID-19 Candidate\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-11-24 22:07 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.benzinga.com/general/biotech/21/11/24269339/fda-denies-breakthrough-tag-for-nrx-pharmas-covid-19-candidate><strong>Benzinga</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Relief Therapeutics Holding SA's collaborating partner NRx Pharmaceuticals Inc has announced that the FDA has denied Breakthrough Therapy Designation for aviptadil.\n\nNRx noted that though the ...</p>\n\n<a href=\"https://www.benzinga.com/general/biotech/21/11/24269339/fda-denies-breakthrough-tag-for-nrx-pharmas-covid-19-candidate\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"RLFTF":"RELIEF THERAPEUTICS HLDG AG","NRXP":"NRX Pharmaceuticals Inc."},"source_url":"https://www.benzinga.com/general/biotech/21/11/24269339/fda-denies-breakthrough-tag-for-nrx-pharmas-covid-19-candidate","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1167653292","content_text":"Relief Therapeutics Holding SA's collaborating partner NRx Pharmaceuticals Inc has announced that the FDA has denied Breakthrough Therapy Designation for aviptadil.\n\nNRx noted that though the designation is not required for drug approval or emergency use authorization, but can afford faster review times, the ability to submit a rolling application, and dedicated FDA review personnel.\nAdditionally, according to the CEO Update, the FDA has already granted priority and rolling review as part of the Fast Track Designation awarded in July 2020.\nTherefore, the denial does not impede NRx's ability to seek drug approval.\nRelief's lead drug candidate, RLF-100 (aviptadil), is a synthetic form of Vasoactive Intestinal Peptide (VIP).\nIt is in late-stage clinical testing in the U.S. for respiratory deficiency due to COVID-19..\nPrice Action: NRXP shares closed 5.56% lower at $4.25 during after-hours trading on Tuesday.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":6708489,"gmtCreate":1637763254538,"gmtModify":1637763254633,"authorId":3555755639757611,"author":{"id":3555755639757611,"idStr":"3555755639757611","authorId":3555755639757611,"name":"nxw","avatar":"https://static.tigerbbs.com/0a3041e78835567c8db5934504534a17","vip":1,"crmLevel":5,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":874879942,"type":1,"supId":0,"prevId":0,"content":"Ok","text":"Ok","html":"Ok"},{"id":6708459,"gmtCreate":1637763149852,"gmtModify":1637763149955,"authorId":3580889175020769,"author":{"id":3580889175020769,"idStr":"3580889175020769","authorId":3580889175020769,"name":"sockbuster","avatar":"https://static.tigerbbs.com/902e4c3353374f5915d6b7fecf6ec383","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":874879942,"type":1,"supId":0,"prevId":0,"content":"<u>ok</u>","text":"<u>ok</u>","html":"<u>ok</u>"},{"id":6708446,"gmtCreate":1637763069680,"gmtModify":1637763069760,"authorId":3578621924333526,"author":{"id":3578621924333526,"idStr":"3578621924333526","authorId":3578621924333526,"name":"ConanToh","avatar":"https://static.tigerbbs.com/17bf1e09858b72f85e5e8efda2fbed84","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":874879942,"type":1,"supId":0,"prevId":0,"content":"good","text":"good","html":"good"}],"langContent":"CN"},{"id":874870662,"gmtCreate":1637762997081,"gmtModify":1637763229183,"author":{"id":"4087473897023050","authorId":"4087473897023050","name":"CW37","avatar":"https://static.tigerbbs.com/8017b0b5389b68d3666c7996d3950287","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"4087473897023050","authorIdStr":"4087473897023050"},"htmlText":"tiger","listText":"tiger","text":"tiger","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/874870662","repostId":1167653292,"repostType":4,"repost":{"id":"1167653292","kind":"news","pubTimestamp":1637762873,"share":"https://www.laohu8.com/m/news/1167653292?lang=&edition=full","pubTime":"2021-11-24 22:07","market":"us","language":"en","title":"FDA Denies Breakthrough Tag For NRx Pharma's COVID-19 Candidate","url":"https://stock-news.laohu8.com/highlight/detail?id=1167653292","media":"Benzinga","summary":"Relief Therapeutics Holding SA's collaborating partner NRx Pharmaceuticals Inc has announced that th","content":"<p><b>Relief Therapeutics Holding SA's</b>&nbsp;collaborating partner&nbsp;<b>NRx Pharmaceuticals Inc</b>&nbsp;has announced that the&nbsp;FDA has denied Breakthrough Therapy Designation&nbsp;for aviptadil.</p>\n<ul>\n <li>NRx noted that though the designation is not required for drug approval or emergency use authorization, but can afford faster review times, the ability to submit a rolling application, and dedicated FDA review personnel.</li>\n <li>Additionally, according to the CEO Update, the FDA has already granted priority and rolling review as part of the Fast Track Designation awarded in July 2020.</li>\n <li>Therefore, the denial does not impede NRx's ability to seek drug approval.</li>\n <li>Relief's lead drug candidate, RLF-100 (aviptadil), is a synthetic form of Vasoactive Intestinal Peptide (VIP).</li>\n <li>It is in late-stage clinical testing in the U.S. for respiratory deficiency due to COVID-19.<i>.</i></li>\n <li><b>Price Action:</b>&nbsp;NRXP shares closed 5.56% lower at $4.25 during after-hours trading on Tuesday.</li>\n</ul>","source":"lsy1606299360108","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>FDA Denies Breakthrough Tag For NRx Pharma's COVID-19 Candidate</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nFDA Denies Breakthrough Tag For NRx Pharma's COVID-19 Candidate\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-11-24 22:07 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.benzinga.com/general/biotech/21/11/24269339/fda-denies-breakthrough-tag-for-nrx-pharmas-covid-19-candidate><strong>Benzinga</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Relief Therapeutics Holding SA's collaborating partner NRx Pharmaceuticals Inc has announced that the FDA has denied Breakthrough Therapy Designation for aviptadil.\n\nNRx noted that though the ...</p>\n\n<a href=\"https://www.benzinga.com/general/biotech/21/11/24269339/fda-denies-breakthrough-tag-for-nrx-pharmas-covid-19-candidate\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"RLFTF":"RELIEF THERAPEUTICS HLDG AG","NRXP":"NRX Pharmaceuticals Inc."},"source_url":"https://www.benzinga.com/general/biotech/21/11/24269339/fda-denies-breakthrough-tag-for-nrx-pharmas-covid-19-candidate","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1167653292","content_text":"Relief Therapeutics Holding SA's collaborating partner NRx Pharmaceuticals Inc has announced that the FDA has denied Breakthrough Therapy Designation for aviptadil.\n\nNRx noted that though the designation is not required for drug approval or emergency use authorization, but can afford faster review times, the ability to submit a rolling application, and dedicated FDA review personnel.\nAdditionally, according to the CEO Update, the FDA has already granted priority and rolling review as part of the Fast Track Designation awarded in July 2020.\nTherefore, the denial does not impede NRx's ability to seek drug approval.\nRelief's lead drug candidate, RLF-100 (aviptadil), is a synthetic form of Vasoactive Intestinal Peptide (VIP).\nIt is in late-stage clinical testing in the U.S. for respiratory deficiency due to COVID-19..\nPrice Action: NRXP shares closed 5.56% lower at $4.25 during after-hours trading on Tuesday.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":6708438,"gmtCreate":1637763002418,"gmtModify":1637763002448,"authorId":4087473897023050,"author":{"id":4087473897023050,"idStr":"4087473897023050","authorId":4087473897023050,"name":"CW37","avatar":"https://static.tigerbbs.com/8017b0b5389b68d3666c7996d3950287","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":874870662,"type":1,"supId":0,"prevId":0,"content":"broker","text":"broker","html":"broker"}],"langContent":"CN"}],"hasMoreComments":true,"newsSizeData":{"likeSize":48,"commentSize":11,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false}}